相关实验视频

Updated: May 15, 2025

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice

Published on: May 16, 2021

AMPK激活剂ATX-304通过代谢切换减少氧化应激并改善MASLD

Emanuel Holm¹, Isabeau Vermeulen², Saba Parween¹

¹Department of Medical and Translational Biology, Umeå University, Umeå Sweden.

|April 8, 2025

概括

AMPK激活剂ATX-304显示出治疗代谢功能障碍相关的脂肪性肝病 (MASLD) 的前景. 它降低了小鼠的脂肪,胆固醇和肝脏肥胖症/纤维化,这表明了新的治疗途径.

科学领域:

肝病学肝病学是一种肝病学.
代谢疾病代谢疾病
药理学药理学是指药理学的学科.

背景情况:

与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一种普遍存在的全球性肝病,治疗选择有限.
氨酸单酸激活蛋白激酶 (AMPK) 是细胞代谢的关键调节剂,也是MASLD的潜在治疗点.
目前,没有直接的AMPK激活剂被批准用于MASLD治疗.

研究的目的:

在前临床小鼠模型中研究AMPK激活剂ATX-304的疗效,研究进展性脂肪肝疾病.
评估ATX-304对体脂质量,血液中的胆固醇,肝硬化和纤维化的影响.
为了阐明ATX-304在肝脏中诱导的潜在代谢变化.

主要方法:

使用了前临床小鼠模型的渐进性脂肪肝疾病.
将AMPK激活器ATX-304注射到模型中.
评估了体脂质量,血中的胆固醇,肝硬化和纤维化的变化.
分析肝脏代谢程序,包括脂肪酸氧化,脂质合成和脂质运输.

主要成果:

ATX-304显著降低了体脂量,降低了血液中的胆固醇水平.
用ATX-304治疗减轻了肝硬化症,并减轻了肝纤维化的发展.
观察到肝脏代谢编程的转变,其特点是脂肪酸氧化增加和脂质合成减少.
在ATX-304治疗后,在肝叶内发现脂质分布和液滴定位的变化.

结论:

ATX-304通过改善关键代谢参数和减少肝脏病理学来证明MASLD的显著治疗潜力.
药物的机制包括增强脂肪酸氧化和重塑脂质代谢.
需要进一步研究ATX-304的局部效应和MASLD的治疗应用.

关键词:

脂肪酸氧化过程中的脂肪酸氧化.胃肠病学胃肠病学肝病学肝病学是一种肝病学.代谢过程中的代谢.肥胖问题肥胖问题文字转录学 (Transcriptomics) 是一个学科.

更多相关视频

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

Author Spotlight: New Insights into PBMC Mitochondrial Responses Using Fluorespirometry

Author Spotlight: New Insights into PBMC Mitochondrial Responses Using Fluorespirometry

Published on: May 24, 2024

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

cAMP-dependent Protein Kinase Pathways

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...